X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
0
Other Certificates
Other Suppliers
0
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
https://www.prnewswire.com/news-releases/upsher-smith-previews-expansion-of-its-rare-disease-portfolio-at-2024-aan-annual-meeting-302115529.html
https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/invagen-pharmaceuticals-issues-voluntary-nationwide-recall-vigabatrin-oral-solution-usp-500mg-due
https://www.prnewswire.com/news-releases/invagen-pharmaceuticals-issues-voluntary-nationwide-recall-of-vigabatrin-for-oral-solution-usp-500mg-due-to-leaking-sachets-302010708.html
https://www.prnewswire.com/news-releases/invagen-pharmaceuticals-issues-voluntary-nationwide-recall-of-vigabatrin-for-oral-solution-usp-500mg-due-to-leaking-sachets-302010708.html
https://recalls-rappels.canada.ca/en/alert-recall/sabril-vigabatrin-500-mg-sachets-found-contain-trace-amounts-another-drug
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-september-6-2023-36272.pdf
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-march-8-2023-15780.pdf
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215363
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213104
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210042
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/lupin-gets-usfda-nod-to-market-generic-drug/articleshow/90155699.cms
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211790
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/zydus-gets-final-us-fda-nod-to-market-generic-version-of-vigabatrin-tablets/articleshow/89011908.cms
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215707
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211290
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213899
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215109
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212626
https://www.businesswire.com/news/home/20210202005524/en/Dr.-Reddys-Laboratories-Announces-the-Launch-of-Vigabatrin-Tablets-USP-in-the-U.S.-Market
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213519
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213375
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211592
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/dr-reddys-launches-generic-oral-anti-epileptic-drug-in-us/articleshow/70756035.cms
https://www.biospectrumasia.com/news/49/14276/dr-reddys-launches-vigabatrin-in-the-us.html
https://www.moneycontrol.com/news/business/stocks/dr-reddys-gains-on-launch-of-vigabatrin-powder-4351921.html
http://www.pmlive.com/pharma_news/lundbecks_key_products_shine_in_q2_but_problems_remain_1297435
https://algosonline.com/news/aucta-partners-with-fosun-pharma-to-market-the-fda-approved-vigabatrin
https://www.worldpharmatoday.com/news/aucta-pharmaceuticals-announces-licensing-of-vigabatrin-for-oral-solution-in-china/
http://www.globenewswire.com/news-release/2018/07/16/1537528/0/en/Aucta-Receives-its-First-Product-Approval-and-Launches-Vigabatrin-for-Oral-Solution-Under-the-Brand-Name-Vigadrone.html
https://www.fiercepharma.com/pharma-asia/foreign-drugmakers-under-threat-as-china-rolls-out-drug-list-to-boost-generic
https://www.biospectrumasia.com/news/34/12759/teva-announces-us-launch-of-vigabatrin.html
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm629569.htm?utm_campaign=FDA%20approves%20first%20generic%20version%20of%20Sabril%20%28vigabatrin%29%20tablets%20-%20Drug%20Information%20Update&utm_medium=email&utm_source=Eloqua
https://www.accessdata.fda.gov/scripts/cder/ob/results_product.cfm?utm_campaign=Generic%20Sabril%20email&utm_medium=email&utm_source=Eloqua&Appl_Type=A&Appl_No=209822&elqTrackId=85f13aac5026441fb1b1a78206883e65&elq=55e967942c134d45b1cb12eac9150903&elqaid=6490&elqat=1&elqCampaignId=5292
https://www.raps.org/news-and-articles/news-articles/2019/1/fda-approves-first-generic-version-of-lundbecks-s?utm_source=MagnetMail&utm_medium=Email%20&utm_campaign=RF%20Today%20%7C%2016%20January
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209822
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211481
https://www.ema.europa.eu/documents/product-information/kigabeq-epar-product-information_en.pdf
https://www.epmmagazine.com/news/catalent-to-formulate-vigabatrin-into-novel-dosage-form/
http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2018/07/news_detail_002998.jsp&mid=WC0b01ac058004d5c1
http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2018/07/news_detail_002994.jsp&mid=WC0b01ac058004d5c1
https://www.globenewswire.com/news-release/2018/07/16/1537528/0/en/Aucta-Receives-its-First-Product-Approval-and-Launches-Vigabatrin-for-Oral-Solution-Under-the-Brand-Name-Vigadrone.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210196
https://www.prnewswire.com/news-releases/amneal-launches-generic-for-sabril-vigabatrin-for-oral-solution-usp-300641073.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209824
http://www.globenewswire.com/news-release/2018/07/16/1537528/0/en/Aucta-Receives-its-First-Product-Approval-and-Launches-Vigabatrin-for-Oral-Solution-Under-the-Brand-Name-Vigadrone.html
Market Place
Share 
